Site Admin

The MAP Gap Newsletter | July 2017

Human Paratuberculosis Foundation is dedicated to providing the most up-to-date information in our field to assist patients around the world in making informed decisions about their treatment. We are grateful for the support of this community and look forward to taking this journey together. Read all the latest news and research about Mycobacterium avium subsp. paratuberculosis (MAP) and the treatment of Crohn’s and other diseases using Anti-MAP therapy. Enjoy!

Read the Newsletter

The MAP Gap Newsletter | April 2017

Human Paratuberculosis Foundation is dedicated to providing the most up-to-date information in our field to assist patients around the world in making informed decisions about their treatment. We are grateful for the support of this community and look forward to taking this journey together. Read all the latest news and research about Mycobacterium avium subsp. paratuberculosis (MAP) and the treatment of Crohn’s and other diseases using AMAT therapy. Enjoy!

Read the Newsletter

Welcome to the Human Paratuberculosis Foundation

The Crohn’s Infection is proud to announce the formation of our new non-profit organization: Human Paratuberculosis Foundation. Human Paratuberculosis Foundation, Inc. is a non-profit organization founded in 2016 under the laws of the State of New York. We are an approved IRS 503(c)(1) charity. In addition, we are happy to let our community know about the 2017 MAP Conference to be held in Philadelphia on March 24-25th. Keep reading for more details and an opportunity to help!

Read the Article

The MAP Gap Newsletter | October 2016

Human Paratuberculosis Foundation is dedicated to providing the most up-to-date information in our field to assist patients around the world in making informed decisions about their treatment. We are grateful for the support of this community and look forward to taking this journey together. Read all the latest news and research about Mycobacterium avium subsp. paratuberculosis (MAP) and the treatment of Crohn’s and other diseases using AMAT therapy. Enjoy!

Read the Newsletter

The MAP Gap Newsletter | July 2016

TCI BannerThe Crohns Infection is dedicated to providing the most up-to-date information in our field to assist patients around the world in making informed decisions about their treatment. We are grateful for the support of this community and look forward to taking this journey together. Here are some of the most recent developments in the area of MAP related Crohn’s Research. Enjoy!

Read the Newsletter

The Dietzia Foundation

cropped-Virus-Micrograph.jpgThe Crohn’s Infection is pleased to announce the newly created Dietzia Foundation! From their website, “Dietzia Foundation is a publicly supported nonprofit organization dedicated to supporting scientific medical research in the field of gastroenterology. Specifically, we support those trying to develop preventative or therapeutic treatments for gastrointestinal dysbiosis associated diseases like Crohn’s disease, ulcerative colitis and others.”

Read the Full Article

AMAT: Together We Are Stronger

TogetherOn June 14, 2016, the journal Gut Pathogens released a new study entitled “RHB-104 Triple Antibiotics Combination in Culture is Bactericidal and Should be Effective for Treatment of Crohn’s Disease Associated with Mycobacterium paratuberculosis.” The researchers from the University of Central Florida (including Dr. Saleh Naser) found that the raw active ingredients used in RHB-104 worked together in combination to inhibit the growth of 16 Mycobacterium avium paratuberculosis (MAP) strains and 19 other mycobacterial species.

Read the Full Article

Dietzia: A Potential Probiotic Therapy for Crohn’s Disease

Dr. Robert E. Click
Dr. Robert E. Click
In this age of organic food, chemical free products, farmer’s markets and going green, it’s no wonder that Dietzia spp. C79793-74 is generating great interest among Crohn’s disease patients. After all, if this emerging probiotic therapy could curtail the symptoms of Crohn’s disease as well as, or even better than, conventional therapies but without the side effects, it may well become the future of Crohn’s treatment. While human research and trials need to be completed, Dietzia has shown promise in cattle infected with Johne’s disease. With new information emerging about this bacterial species, we thought our readers would enjoy this timely overview. We are honored to introduce the man who discovered benefits of Dietzia spp. C79793-74, Dr. Robert E. Click.

Read the Full Article